Streptomyces toxytricini for high yield of lipstatin and fermentation medium thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BIOTOOL LLC
- Publication Date
- 2015-07-22
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of fermentation engineering, and in particular relates to a strain of Streptomyces toxin, which has the performance of high-yielding riprestatin. The invention also relates to a fermentation medium for the strain. Background technique
[0002] Liprestatin is an endogenous lipase inhibitor produced by streptomyces toxytricini, and its tetrahydro derivative orlistat is currently the only weight-loss drug marketed as a non-central nervous system effect [1] . Orlistat has been certified by the FDA and currently occupies 2 / 3 of the weight loss drug market. Orlistat can selectively inhibit the activity of pancreatic lipase in the intestinal tract. As a "fat blocking agent", it only exerts pharmacological effects in the gastrointestinal tract and can prevent about 30% of dietary triglycerides from being digested and absorbed , On the basis of food therapy, calorie intake can be further reduced. Orlistat's high selectivit...